Literature DB >> 24854892

Mechanistic modeling of monocarboxylate transporter-mediated toxicokinetic/toxicodynamic interactions between γ-hydroxybutyrate and L-lactate.

Bridget L Morse1, Nisha Vijay, Marilyn E Morris.   

Abstract

Overdose of γ-hydroxybutyrate (GHB) can result in severe respiratory depression. Monocarboxylate transporter (MCT) inhibitors, including L-lactate, increase GHB clearance and represent a potential treatment for GHB intoxication. GHB can also affect L-lactate clearance, and L-lactate has been reported to affect respiration. In this research, we characterize these toxicokinetic/toxicodynamic interactions between GHB and L-lactate using mechanistic modeling. Plasma, urine, and respiration data were taken from our previous study in which GHB and sodium L-lactate were administered alone and concomitantly in rats. A model incorporating active renal reabsorption for both agents fit GHB and L-lactate toxicokinetic data. The Km for renal reabsorption of GHB (650 μg/mL) was close to its Km for the proton-dependent MCT1 and that for L-lactate (13.5 μg/mL) close to its Km for the sodium-dependent SMCT1. Inhibition of reabsorption by both agents was necessary to model concomitant drug administration. The metabolic Km for L-lactate closely resembled that for MCT-mediated hepatic uptake in vitro, and GHB inhibited this process. L-lactate significantly inhibited respiration at a high dose, and an indirect response model was used to fit these data. GHB toxicodynamics was modeled as a direct effect delayed by nonlinear transport into the brain extracellular fluid, with a Km value of 1,865 μg/mL for brain uptake which is similar to the in vitro Km value determined in rat brain endothelial cells. This model was useful for characterizing multiple MCT-mediated interactions. Incorporation of many parameters that can be determined in vitro may allow for clinical translation of these interactions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24854892      PMCID: PMC4070269          DOI: 10.1208/s12248-014-9593-8

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  32 in total

1.  Concentration-effect relationships for the drug of abuse gamma-hydroxybutyric acid.

Authors:  Melanie A Felmlee; Samuel A Roiko; Bridget L Morse; Marilyn E Morris
Journal:  J Pharmacol Exp Ther       Date:  2010-03-09       Impact factor: 4.030

2.  Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat.

Authors:  J T Lettieri; H L Fung
Journal:  J Pharmacol Exp Ther       Date:  1979-01       Impact factor: 4.030

3.  γ-Hydroxybutyrate blood/plasma partitioning: effect of physiologic pH on transport by monocarboxylate transporters.

Authors:  Bridget L Morse; Melanie A Felmlee; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2011-10-05       Impact factor: 3.922

4.  Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers.

Authors:  P Palatini; L Tedeschi; G Frison; R Padrini; R Zordan; R Orlando; L Gallimberti; G L Gessa; S D Ferrara
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Brain extracellular γ-hydroxybutyrate concentrations are decreased by L-lactate in rats: role in the treatment of overdoses.

Authors:  Samuel A Roiko; Nisha Vijay; Melanie A Felmlee; Marilyn E Morris
Journal:  Pharm Res       Date:  2013-01-15       Impact factor: 4.200

6.  The drug of abuse gamma-hydroxybutyrate is a substrate for sodium-coupled monocarboxylate transporter (SMCT) 1 (SLC5A8): characterization of SMCT-mediated uptake and inhibition.

Authors:  Dapeng Cui; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2009-04-23       Impact factor: 3.922

7.  Effects of sodium lactate on ventilation and acid-base balance in healthy humans.

Authors:  L Tappy; M C Cayeux; R Chioléro
Journal:  Clin Physiol       Date:  1996-07

8.  Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia.

Authors:  David G E Caldicott; Fiona Y Chow; Brian J Burns; Peter D Felgate; Roger W Byard
Journal:  Med J Aust       Date:  2004-09-20       Impact factor: 7.738

9.  γ-Hydroxybutyrate (GHB)-induced respiratory depression: combined receptor-transporter inhibition therapy for treatment in GHB overdose.

Authors:  Bridget L Morse; Nisha Vijay; Marilyn E Morris
Journal:  Mol Pharmacol       Date:  2012-05-04       Impact factor: 4.436

10.  The role of monocarboxylate transporter 2 and 4 in the transport of gamma-hydroxybutyric acid in mammalian cells.

Authors:  Qi Wang; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2007-05-14       Impact factor: 3.922

View more
  6 in total

1.  The Drug of Abuse Gamma-Hydroxybutyric Acid Exhibits Tissue-Specific Nonlinear Distribution.

Authors:  Melanie A Felmlee; Bridget L Morse; Kristin E Follman; Marilyn E Morris
Journal:  AAPS J       Date:  2017-12-26       Impact factor: 4.009

2.  γ-Hydroxybutyric Acid (GHB) Pharmacokinetics and Pharmacodynamics: Semi-Mechanistic and Physiologically Relevant PK/PD Model.

Authors:  Rutwij A Dave; Kristin E Follman; Marilyn E Morris
Journal:  AAPS J       Date:  2017-06-26       Impact factor: 4.009

3.  A Novel Monocarboxylate Transporter Inhibitor as a Potential Treatment Strategy for γ-Hydroxybutyric Acid Overdose.

Authors:  Nisha Vijay; Bridget L Morse; Marilyn E Morris
Journal:  Pharm Res       Date:  2014-12-06       Impact factor: 4.200

4.  Semi-mechanistic kidney model incorporating physiologically-relevant fluid reabsorption and transporter-mediated renal reabsorption: pharmacokinetics of γ-hydroxybutyric acid and L-lactate in rats.

Authors:  Rutwij A Dave; Marilyn E Morris
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-04       Impact factor: 2.745

Review 5.  Regulation of colonic epithelial butyrate transport: Focus on colorectal cancer.

Authors:  Pedro Gonçalves; Fátima Martel
Journal:  Porto Biomed J       Date:  2016-07-01

Review 6.  γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology.

Authors:  Melanie A Felmlee; Bridget L Morse; Marilyn E Morris
Journal:  AAPS J       Date:  2021-01-08       Impact factor: 4.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.